Literature DB >> 21117067

High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival.

Anna M Halldórsdóttir1, Birgitta Sander, Hanna Göransson, Anders Isaksson, Eva Kimby, Mahmoud Mansouri, Richard Rosenquist, Hans Ehrencrona.   

Abstract

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) and numerous copy number aberrations (CNAs). Recently, gene expression profiling defined a proliferation gene expression signature in MCL where high scores predict shorter survival. We investigated 31 MCL cases using high-density single nucleotide polymorphism arrays and correlated CNA patterns with the proliferation signature and with clinical data. Many recurrent CNAs typical of MCL were detected, including losses at 1p (55%), 8p (29%), 9q (29%), 11q (55%), 13q (42%) and 17p (32%), and gains at 3q (39%), 8q (26%), 15q (23%) and 18q (23%). A novel deleted region at 20q (16%) contained only one candidate gene, ZFP64, a putative tumor suppressor. Unsupervised clustering identified subgroups with different patterns of CNAs, including a subset (19%) characterized by the presence of 11q loss in all cases and by the absence of 13q loss, and 3q and 7p gains. Losses at 1p, 8p, 13q and 17p were associated with increased genomic complexity. High proliferation signature scores correlated with increased number of large (>15 Mbp) CNAs (P = 0.03) as well as copy number gains at 7p (P = 0.02) and losses at 9q (P = 0.04). Furthermore, large/complex 13q losses were associated with improved survival (P < 0.05) as were losses/copy number neutral LOH at 19p13 (P = 0.01). In summary, this high-resolution genomic analysis identified novel aberrations and revealed that several CNAs correlated with genomic complexity, the proliferation status and survival.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21117067     DOI: 10.1002/gcc.20836

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

Review 1.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

2.  Lkb1 deletion in murine B lymphocytes promotes cell death and cancer.

Authors:  George P Souroullas; Yuri Fedoriw; Louis M Staudt; Norman E Sharpless
Journal:  Exp Hematol       Date:  2017-04-21       Impact factor: 3.084

3.  Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors.

Authors:  Nelson Lourenço; Zofia Hélias-Rodzewicz; Jean-Baptiste Bachet; Sabrina Brahimi-Adouane; Fabrice Jardin; Jeanne Tran van Nhieu; Frédérique Peschaud; Emmanuel Martin; Alain Beauchet; Frédéric Chibon; Jean-François Emile
Journal:  Mol Cancer       Date:  2014-11-06       Impact factor: 27.401

4.  Blastoid variant mantle cell lymphoma with complex karyotype including 11q duplication.

Authors:  Ozge Ozer; Selami Koçak Toprak; Enver Ote; Zerrin Yılmaz; Feride Iffet Sahin
Journal:  Turk J Haematol       Date:  2014-09-05       Impact factor: 1.831

5.  Investigation of Rho-Kinase Expressions and Polymorphisms in Mantle Cell Lymphoma Patients.

Authors:  Didar Yanardağ Açık; Mehmet Yılmaz; İbrahim Sarı; Serdar Öztuzcu; Zeynel A Sayıner; Salih Subari; Abdullah T Demiryürek
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

6.  Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.

Authors:  Mengxuan Zhu; Pengfei Zhang; Shan Yu; Cheng Tang; Yan Wang; Zhenbin Shen; Weidong Chen; Tianshu Liu; Yuehong Cui
Journal:  J Exp Clin Cancer Res       Date:  2022-01-07

7.  Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.

Authors:  Shuhua Yi; Yuting Yan; Meiling Jin; Supriyo Bhattacharya; Yi Wang; Yiming Wu; Lu Yang; Eva Gine; Guillem Clot; Lu Chen; Ying Yu; Dehui Zou; Jun Wang; An T Phan; Rui Cui; Fei Li; Qi Sun; Qiongli Zhai; Tingyu Wang; Zhen Yu; Lanting Liu; Wei Liu; Rui Lyv; Weiwei Sui; Wenyang Huang; Wenjie Xiong; Huijun Wang; Chengwen Li; Zhijian Xiao; Mu Hao; Jianxiang Wang; Tao Cheng; Silvia Bea; Alex F Herrera; Alexey Danilov; Elias Campo; Vu N Ngo; Lugui Qiu; Lili Wang
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.